Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers | Zendy

Nishant Mohan | Zendy; Jiangsong Jiang | Zendy; Milos Dokmanovic | Zendy; Wen Jin Wu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers

Author(s) -

Nishant Mohan,

Jiangsong Jiang,

Milos Dokmanovic,

Wen Jin Wu

Publication year - 2018

Publication title -

antibody therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.579

H-Index - 5

ISSN - 2516-4236

DOI - 10.1093/abt/tby003

Subject(s) - trastuzumab , cardiotoxicity , medicine , oncology , cancer , metastatic breast cancer , breast cancer , lapatinib , monoclonal antibody , chemotherapy , antibody , immunology

Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associated with its clinical application poses challenges for clinicians and patients, mechanisms of which are still evolving. This review will summarize the current mechanistic understanding of trastuzumab-mediated cardiotoxicity, discuss the novel role of DNA topoisomerase IIB as a shared target for enhanced cardiotoxicity induced by trastuzumab and anthracyclines-based combination regimens, and speculate the potential impact of trastuzumab intervention in immune checkpoint inhibitors-based therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research